Merck Suspends Lobbying For Cervical Cancer Vaccine

Tuesday, February 20th 2007, 5:00 pm

By: News On 6

TRENTON, N.J. (AP) _ Merck & Co., bowing to pressure from parents and medical groups, is immediately suspending its lobbying campaign to persuade state legislatures to mandate that adolescent girls get the company's new vaccine against cervical cancer as a requirement for school attendance.

The drug maker, which announced the change Tuesday, had been criticized for quietly funding the campaign, via a third party, to require 11- and 12-year-old girls get the three-dose vaccine in order to attend school.

Some had objected because the vaccine protects against a sexually transmitted disease, human papilloma virus, which causes cervical cancer. Vaccines mandated for school attendance usually are for diseases easily spread through casual contact, such as measles and mumps.

``Our goal is about cervical cancer prevention and we want to reach as many females as possible with Gardasil,'' Dr. Richard M. Haupt, Merck's medical director for vaccines, told The Associated Press.

``We're concerned that our role in supporting school requirements is a distraction from that goal, and as such have suspended our lobbying efforts,'' Haupt said, adding the company will continue providing information about the vaccine if requested by government officials.

Merck launched Gardasil, the first vaccine to prevent cervical cancer, in June.

Sales totaled $235 million through the end of 2006, according to Merck.

Last month, the AP reported that Merck was channeling money for its state-mandate campaign through Women in Government, an advocacy group made up of female state legislators across the country.

Conservative groups opposed the campaign, saying it would encourage premarital sex, and parents' rights groups said it interfered with their control over their children.

Even two of the prominent medical groups that supported broad use of the vaccine, the American Academy of Pediatricians and the American Academy of Family Practitioners, questioned Merck's timing, Haupt said Tuesday.

``They, along with some other folks in the public health community, believe there needs to be more time,'' he said, to ensure government funding for the vaccine for uninsured girls is in place and that families and government officials have enough information about it.

Legislatures in roughly 20 states have introduced measures that would mandate girls have the vaccine to attend school, but none has passed so far. However, Texas Gov. Rick Perry on Feb. 2 issued an executive order requiring that schoolgirls get the vaccinations, triggering protests from lawmakers in that state, who may seek to pass a law overturning the order.

The National Vaccine Information Center has been publicizing reports of side effects _ mostly dizziness and fainting _ in several dozen people getting Gardasil, which is approved for use in females ages 9 to 26. The center, a group of parents worried that vaccines harm some children, questions whether the vaccine was tested in enough young girls.

Officials with the Centers for Disease Control and Prevention, however, say that reports of side effects through the end of January don't raise any red flags.

The vaccine also is controversial because of its price _ $360 for the three doses required over a six-month stretch. Because of that cost and what pediatricians and gynecologists say is inadequate reimbursement by insurers, many are choosing not to stock the vaccine or requiring surcharges to administer it, increasing the cost for many families and making the vaccine hard to come by.

Merck shares were down in after-hours trading on the New York Stock Exchange, falling 35 cents to $44.15 after rising 22 cents in regular trading to close at $44.50.